Japan Contract Development & Manufacturing Organizations Market Size, Share & Trends Analysis Report By Product (API, Drug Product), By Workflow, By Application (Oncology, Hormonal, Glaucoma, CVD), By Service, By End Use, And Segment Forecasts, 2025 - 2030
This report can be delivered to the clients within 2 Business Days
Japan Contract Development & Manufacturing Organizations Market Growth & Trends
The Japan contract development and manufacturing organizations market size is estimated to reach USD 20.76 billion by 2030, expanding at a CAGR of 7.77% from 2025 to 2030, according to a new report by Grand View Research, Inc. The increasing demand for biopharmaceuticals, a high burden of diseases, and the rising geriatric population are some of the key growth drivers. Growing investments by various Contract Development and Manufacturing Organizations (CDMOs) for facility and service expansion are likely to boost the market over the forecast period.
In addition, increasing pharmaceutical R&D investments are driving the market growth. As pharmaceutical companies invest more in R&D, they may seek external expertise and resources to accelerate drug development processes. CDMOs provide specialized services in drug development, manufacturing, and testing, making them valuable partners for pharmaceutical companies looking to outsource certain aspects of their R&D activities. Several players are investing in the R&D activities of pharmaceuticals. For instance, in March 2022, WuXi AppTec launched Tetracycline-Enabled Self-Silencing Adenovirus (TESSA) technology to accelerate the production of adeno-associated viruses for drugs in cell and gene therapy.
The increase in outsourcing services by pharmaceutical companies in the pharmaceutical industry has profoundly impacted the Japan market. The trend of outsourcing activities in the pharmaceutical domain is rising as companies find value in acquiring additional competencies essential for successful drug development & commercialization. Besides providing extended expertise & assisting in improved cash flow management, outsourcing brings significant manufacturing advantages, including reducing investment risks.
Notably, regulatory authorities in Japan have accelerated approval for regenerative medical and gene therapy products. For instance, the adoption of the Pharmaceuticals and Medical Devices Act (PMD Act), 21st Century Cures Act, and PRIME (Priority Medicines) Initiative has helped the country improve access to regenerative medicines. Such initiatives by regulatory agencies are expected to improve the demand for the development and manufacturing of regenerative medicines in the country.
Japan Contract Development & Manufacturing Organizations Market Report Highlights
LabCorp
Wuxi AppTec, Inc.
Lonza
Recipharm AB
Samsung Biologics
Catalent, Inc.
CordenPharma International
Cambrex Corporation
Thermo Fisher Scientific, Inc.
FUJIFILM Diosynth Biotechnologies
Sumitomo Chemical Company, Limited
CMIC HOLDINGS Co., LTD.
Bushu Pharmaceuticals Ltd.
Nipro Corporation
Japan Contract Development & Manufacturing Organizations Market Growth & Trends
The Japan contract development and manufacturing organizations market size is estimated to reach USD 20.76 billion by 2030, expanding at a CAGR of 7.77% from 2025 to 2030, according to a new report by Grand View Research, Inc. The increasing demand for biopharmaceuticals, a high burden of diseases, and the rising geriatric population are some of the key growth drivers. Growing investments by various Contract Development and Manufacturing Organizations (CDMOs) for facility and service expansion are likely to boost the market over the forecast period.
In addition, increasing pharmaceutical R&D investments are driving the market growth. As pharmaceutical companies invest more in R&D, they may seek external expertise and resources to accelerate drug development processes. CDMOs provide specialized services in drug development, manufacturing, and testing, making them valuable partners for pharmaceutical companies looking to outsource certain aspects of their R&D activities. Several players are investing in the R&D activities of pharmaceuticals. For instance, in March 2022, WuXi AppTec launched Tetracycline-Enabled Self-Silencing Adenovirus (TESSA) technology to accelerate the production of adeno-associated viruses for drugs in cell and gene therapy.
The increase in outsourcing services by pharmaceutical companies in the pharmaceutical industry has profoundly impacted the Japan market. The trend of outsourcing activities in the pharmaceutical domain is rising as companies find value in acquiring additional competencies essential for successful drug development & commercialization. Besides providing extended expertise & assisting in improved cash flow management, outsourcing brings significant manufacturing advantages, including reducing investment risks.
Notably, regulatory authorities in Japan have accelerated approval for regenerative medical and gene therapy products. For instance, the adoption of the Pharmaceuticals and Medical Devices Act (PMD Act), 21st Century Cures Act, and PRIME (Priority Medicines) Initiative has helped the country improve access to regenerative medicines. Such initiatives by regulatory agencies are expected to improve the demand for the development and manufacturing of regenerative medicines in the country.
Japan Contract Development & Manufacturing Organizations Market Report Highlights
- The active pharmaceutical ingredient (API) segment dominated the market with a share of 81.14% in 2024. The segment growth is driven by competitive drug development and growing demand for end-to-end Contract Development & Manufacturing Organization (CDMO) services. In addition, advancements in API manufacturing, growth of the biopharmaceutical sector, and the increasing geriatric population are some of the key factors propelling segment growth
- Based on workflow, the commercial segment held the largest market share in 2024, attributed to robust demand for pharmaceutical products, such as biosimilar medications, generic medications, and regenerative therapies. This is where commercial CDMOs may help by providing knowledge, saving time, and being cost-effective.
- Based on application, the oncology segment dominated the Japan CDMO industry in 2024, owing to the high cancer burden in the country. Approval of regenerative products and virotherapy for cancer treatment can further support market growth and the segment is further driven by increasing number of cancer cases globally. In addition, increasing pharmaceutical R&D investments, patent expirations, and demand for oncology drugs & biologic innovations are the factors driving the oncology segment growth
LabCorp
Wuxi AppTec, Inc.
Lonza
Recipharm AB
Samsung Biologics
Catalent, Inc.
CordenPharma International
Cambrex Corporation
Thermo Fisher Scientific, Inc.
FUJIFILM Diosynth Biotechnologies
Sumitomo Chemical Company, Limited
CMIC HOLDINGS Co., LTD.
Bushu Pharmaceuticals Ltd.
Nipro Corporation
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market Segmentation & Scope
1.1.1. Estimates and forecasts timeline.
1.2. Market Definitions
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Bottom Up Approach (Model 2)
1.7.3. Value Chain Based Approach (Model 3)
1.7.4. Multivariate Analysis (Model 4)
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
CHAPTER 3. JAPAN CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Growing Demand for Biopharmaceutical Drugs in Japan
3.2.1.2. High Geriatric Population And Growing Disease Burden in Japan
3.2.1.3. Low Cost Associated with Outsourcing Drug Manufacturing and Development Services
3.2.2. Market Restraint Analysis
3.2.2.1. Limited Outsourcing Opted by Big Pharma Companies
3.2.2.2. Quality Issues While Outsourcing
3.3. Pricing Model Analysis
3.4. Technology Landscape
3.5. Business Model Analysis
3.6. Regulatory Framework
3.7. Clinical Trials Volume Analysis, 2024
3.7.1. Total Number of Clinical Trials, by Phase (2024)
3.7.2. Total Number of Clinical Trials, by Study Design (2024)
3.7.3. Total Number of Clinical Trials, by Key Therapeutic Area (2024)
3.8. Japan Contract Development and Manufacturing Organizations Market Analysis Tools
3.8.1. Porter’s Five Forces Analysis
3.8.2. PESTEL Analysis
3.8.3. COVID-19 Impact Analysis
CHAPTER 4. JAPAN CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS MARKET: PRODUCT ESTIMATES & TREND ANALYSIS
4.1. Segment Dashboard
4.2. Japan Contract Development and Manufacturing Organizations Market: Product Movement Analysis
4.3. Japan Contract Development and Manufacturing Organizations Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
4.4. API
4.4.1. API Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.2. Type
4.4.2.1. Traditional Active Pharmaceutical Ingredient (Traditional API)
4.4.2.1.1. Traditional Active Pharmaceutical Ingredient (Traditional API) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.2.2. Highly Potent Active Pharmaceutical Ingredient (HP-API)
4.4.2.2.1. Highly Potent Active Pharmaceutical Ingredient (HP-API) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.2.3. Antibody Drug Conjugate (ADC)
4.4.2.3.1. Antibody Drug Conjugate (ADC) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.2.4. Others
4.4.2.4.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.3. Synthesis
4.4.3.1. Synthetic
4.4.3.1.1. Synthetic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.3.1.2. Solid
4.4.3.1.2.1. Solid Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.3.1.3. Liquid
4.4.3.1.3.1. Liquid Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.3.2. Biotech
4.4.3.2.1. Biotech Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.4. Drug
4.4.4.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.4.2. Innovative
4.4.4.2.1. Innovative Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.4.3. Generics
4.4.4.3.1. Generics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.5. Manufacturing
4.4.5.1. Continuous manufacturing
4.4.5.1.1. Continuous Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.5.2. Batch manufacturing
4.4.5.2.1. Batch Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Drug Product
4.5.1. By Drug Type
4.5.1.1. Oral Solid Dose
4.5.1.1.1. Oral Solid Dose Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.1.2. Semi-Solid Dose
4.5.1.2.1. Semi-Solid Dose Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.1.3. Liquid Dose
4.5.1.3.1. Liquid Dose Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.1.4. Others
4.5.1.4.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.2. By Type
4.5.2.1. Innovative
4.5.2.1.1. Innovative Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.2.2. Generic
4.5.2.2.1. Generic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.3. By Molecule
4.5.3.1. Small Molecule
4.5.3.1.1. Small Molecule Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.3.2. Large Molecule
4.5.3.2.1. Large Molecule Market Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 5. JAPAN CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS MARKET: WORKFLOW ESTIMATES & TREND ANALYSIS
5.1. Segment Dashboard
5.2. Japan Contract Development and Manufacturing Organizations Market: Workflow Movement Analysis
5.3. Japan Contract Development and Manufacturing Organizations Market Size & Trend Analysis, by Workflow, 2018 to 2030 (USD Million)
5.4. Clinical
5.4.1. Clinical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. Commercial
5.5.1. Commercial Market Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 6. JAPAN CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS MARKET: APPLICATION ESTIMATES & TREND ANALYSIS
6.1. Segment Dashboard
6.2. Japan Contract Development and Manufacturing Organizations Market: Application Movement Analysis
6.3. Japan Contract Development and Manufacturing Organizations Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
6.4. Oncology
6.4.1. Oncology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Hormonal
6.5.1. Hormonal Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6. Glaucoma
6.6.1. Glaucoma Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.7. Cardiovascular Diseases
6.7.1. Cardiovascular Diseases Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.8. Diabetes
6.8.1. Diabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.9. Others
6.9.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 7. JAPAN CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS MARKET: SERVICE ESTIMATES & TREND ANALYSIS
7.1. Segment Dashboard
7.2. Japan Contract Development and Manufacturing Organizations Market: Service Movement Analysis
7.3. Japan Contract Development and Manufacturing Organizations Market Size & Trend Analysis, by Service, 2018 to 2030 (USD Million)
7.4. Contract Development
7.4.1. Contract Development Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Contract Manufacturing
7.5.1. Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6. Packaging
7.6.1. Packaging Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.7. Quality Control and Assurance
7.7.1. Quality Control and Assurance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.7.2. Visual Inspection
7.7.2.1. Visual Inspection Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.7.3. Others
7.7.3.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.8. Others
7.8.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 8. JAPAN CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS MARKET: END USE ESTIMATES & TREND ANALYSIS
8.1. Segment Dashboard
8.2. Japan Contract Development and Manufacturing Organizations Market: End Use Movement Analysis
8.3. Japan Contract Development and Manufacturing Organizations Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
8.4. Pharmaceutical Companies
8.4.1. Pharmaceutical Companies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.5. Biotechnology Companies
8.5.1. Biotechnology Companies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.6. Others
8.6.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 9. JAPAN CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS MARKET: COMPETITIVE LANDSCAPE
9.1. Market Participant Categorization
9.1.1. Market Leaders
9.1.2. Emerging Players
9.2. Company Market Assessment Analysis, 2024
9.3. Company Profiles
9.3.1. LabCorp
9.3.1.1. Company Overview
9.3.1.2. Financial Performance
9.3.1.3. Service Benchmarking
9.3.1.4. Strategic Initiatives
9.3.2. Wuxi AppTec, Inc.
9.3.2.1. Company Overview
9.3.2.2. Financial Performance
9.3.2.3. Service Benchmarking
9.3.2.4. Strategic Initiatives
9.3.3. Lonza
9.3.3.1. Company Overview
9.3.3.2. Financial Performance
9.3.3.3. Service Benchmarking
9.3.3.4. Strategic Initiatives
9.3.4. Recipharm AB
9.3.4.1. Company Overview
9.3.4.2. Financial Performance
9.3.4.3. Service Benchmarking
9.3.4.4. Strategic Initiatives
9.3.5. Samsung Biologics
9.3.5.1. Company Overview
9.3.5.2. Financial Performance
9.3.5.3. Service Benchmarking
9.3.5.4. Strategic Initiatives
9.3.6. Catalent, Inc.
9.3.6.1. Company Overview
9.3.6.2. Financial Performance
9.3.6.3. Service Benchmarking
9.3.6.4. Strategic Initiatives
9.3.7. CordenPharma International
9.3.7.1. Company Overview
9.3.7.2. Financial Performance
9.3.7.3. Service Benchmarking
9.3.7.4. Strategic Initiatives
9.3.8. Cambrex Corporation
9.3.8.1. Company Overview
9.3.8.2. Financial Performance
9.3.8.3. Service Benchmarking
9.3.8.4. Strategic Initiatives
9.3.9. Thermo Fisher Scientific, Inc.
9.3.9.1. Company Overview
9.3.9.2. Financial Performance
9.3.9.3. Service Benchmarking
9.3.9.4. Strategic Initiatives
9.3.10. FUJIFILM Diosynth Biotechnologies
9.3.10.1. Company Overview
9.3.10.2. Financial Performance
9.3.10.3. Service Benchmarking
9.3.10.4. Strategic Initiatives
9.3.11. Sumitomo Chemical Company, Limited
9.3.11.1. Company Overview
9.3.11.2. Financial Performance
9.3.11.3. Service Benchmarking
9.3.11.4. Strategic Initiatives
9.3.12. CMIC HOLDINGS Co., LTD.
9.3.12.1. Company Overview
9.3.12.2. Financial Performance
9.3.12.3. Service Benchmarking
9.3.12.4. Strategic Initiatives
9.3.13. Bushu Pharmaceuticals Ltd.
9.3.13.1. Company Overview
9.3.13.2. Financial Performance
9.3.13.3. Service Benchmarking
9.3.13.4. Strategic Initiatives
9.3.14. Nipro Corporation
9.3.14.1. Company Overview
9.3.14.2. Financial Performance
9.3.14.3. Service Benchmarking
9.3.14.4. Strategic Initiatives
1.1. Market Segmentation & Scope
1.1.1. Estimates and forecasts timeline.
1.2. Market Definitions
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Bottom Up Approach (Model 2)
1.7.3. Value Chain Based Approach (Model 3)
1.7.4. Multivariate Analysis (Model 4)
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
CHAPTER 3. JAPAN CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Growing Demand for Biopharmaceutical Drugs in Japan
3.2.1.2. High Geriatric Population And Growing Disease Burden in Japan
3.2.1.3. Low Cost Associated with Outsourcing Drug Manufacturing and Development Services
3.2.2. Market Restraint Analysis
3.2.2.1. Limited Outsourcing Opted by Big Pharma Companies
3.2.2.2. Quality Issues While Outsourcing
3.3. Pricing Model Analysis
3.4. Technology Landscape
3.5. Business Model Analysis
3.6. Regulatory Framework
3.7. Clinical Trials Volume Analysis, 2024
3.7.1. Total Number of Clinical Trials, by Phase (2024)
3.7.2. Total Number of Clinical Trials, by Study Design (2024)
3.7.3. Total Number of Clinical Trials, by Key Therapeutic Area (2024)
3.8. Japan Contract Development and Manufacturing Organizations Market Analysis Tools
3.8.1. Porter’s Five Forces Analysis
3.8.2. PESTEL Analysis
3.8.3. COVID-19 Impact Analysis
CHAPTER 4. JAPAN CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS MARKET: PRODUCT ESTIMATES & TREND ANALYSIS
4.1. Segment Dashboard
4.2. Japan Contract Development and Manufacturing Organizations Market: Product Movement Analysis
4.3. Japan Contract Development and Manufacturing Organizations Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
4.4. API
4.4.1. API Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.2. Type
4.4.2.1. Traditional Active Pharmaceutical Ingredient (Traditional API)
4.4.2.1.1. Traditional Active Pharmaceutical Ingredient (Traditional API) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.2.2. Highly Potent Active Pharmaceutical Ingredient (HP-API)
4.4.2.2.1. Highly Potent Active Pharmaceutical Ingredient (HP-API) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.2.3. Antibody Drug Conjugate (ADC)
4.4.2.3.1. Antibody Drug Conjugate (ADC) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.2.4. Others
4.4.2.4.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.3. Synthesis
4.4.3.1. Synthetic
4.4.3.1.1. Synthetic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.3.1.2. Solid
4.4.3.1.2.1. Solid Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.3.1.3. Liquid
4.4.3.1.3.1. Liquid Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.3.2. Biotech
4.4.3.2.1. Biotech Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.4. Drug
4.4.4.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.4.2. Innovative
4.4.4.2.1. Innovative Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.4.3. Generics
4.4.4.3.1. Generics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.5. Manufacturing
4.4.5.1. Continuous manufacturing
4.4.5.1.1. Continuous Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.5.2. Batch manufacturing
4.4.5.2.1. Batch Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Drug Product
4.5.1. By Drug Type
4.5.1.1. Oral Solid Dose
4.5.1.1.1. Oral Solid Dose Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.1.2. Semi-Solid Dose
4.5.1.2.1. Semi-Solid Dose Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.1.3. Liquid Dose
4.5.1.3.1. Liquid Dose Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.1.4. Others
4.5.1.4.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.2. By Type
4.5.2.1. Innovative
4.5.2.1.1. Innovative Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.2.2. Generic
4.5.2.2.1. Generic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.3. By Molecule
4.5.3.1. Small Molecule
4.5.3.1.1. Small Molecule Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.3.2. Large Molecule
4.5.3.2.1. Large Molecule Market Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 5. JAPAN CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS MARKET: WORKFLOW ESTIMATES & TREND ANALYSIS
5.1. Segment Dashboard
5.2. Japan Contract Development and Manufacturing Organizations Market: Workflow Movement Analysis
5.3. Japan Contract Development and Manufacturing Organizations Market Size & Trend Analysis, by Workflow, 2018 to 2030 (USD Million)
5.4. Clinical
5.4.1. Clinical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. Commercial
5.5.1. Commercial Market Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 6. JAPAN CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS MARKET: APPLICATION ESTIMATES & TREND ANALYSIS
6.1. Segment Dashboard
6.2. Japan Contract Development and Manufacturing Organizations Market: Application Movement Analysis
6.3. Japan Contract Development and Manufacturing Organizations Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
6.4. Oncology
6.4.1. Oncology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Hormonal
6.5.1. Hormonal Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6. Glaucoma
6.6.1. Glaucoma Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.7. Cardiovascular Diseases
6.7.1. Cardiovascular Diseases Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.8. Diabetes
6.8.1. Diabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.9. Others
6.9.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 7. JAPAN CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS MARKET: SERVICE ESTIMATES & TREND ANALYSIS
7.1. Segment Dashboard
7.2. Japan Contract Development and Manufacturing Organizations Market: Service Movement Analysis
7.3. Japan Contract Development and Manufacturing Organizations Market Size & Trend Analysis, by Service, 2018 to 2030 (USD Million)
7.4. Contract Development
7.4.1. Contract Development Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Contract Manufacturing
7.5.1. Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6. Packaging
7.6.1. Packaging Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.7. Quality Control and Assurance
7.7.1. Quality Control and Assurance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.7.2. Visual Inspection
7.7.2.1. Visual Inspection Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.7.3. Others
7.7.3.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.8. Others
7.8.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 8. JAPAN CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS MARKET: END USE ESTIMATES & TREND ANALYSIS
8.1. Segment Dashboard
8.2. Japan Contract Development and Manufacturing Organizations Market: End Use Movement Analysis
8.3. Japan Contract Development and Manufacturing Organizations Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
8.4. Pharmaceutical Companies
8.4.1. Pharmaceutical Companies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.5. Biotechnology Companies
8.5.1. Biotechnology Companies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.6. Others
8.6.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 9. JAPAN CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS MARKET: COMPETITIVE LANDSCAPE
9.1. Market Participant Categorization
9.1.1. Market Leaders
9.1.2. Emerging Players
9.2. Company Market Assessment Analysis, 2024
9.3. Company Profiles
9.3.1. LabCorp
9.3.1.1. Company Overview
9.3.1.2. Financial Performance
9.3.1.3. Service Benchmarking
9.3.1.4. Strategic Initiatives
9.3.2. Wuxi AppTec, Inc.
9.3.2.1. Company Overview
9.3.2.2. Financial Performance
9.3.2.3. Service Benchmarking
9.3.2.4. Strategic Initiatives
9.3.3. Lonza
9.3.3.1. Company Overview
9.3.3.2. Financial Performance
9.3.3.3. Service Benchmarking
9.3.3.4. Strategic Initiatives
9.3.4. Recipharm AB
9.3.4.1. Company Overview
9.3.4.2. Financial Performance
9.3.4.3. Service Benchmarking
9.3.4.4. Strategic Initiatives
9.3.5. Samsung Biologics
9.3.5.1. Company Overview
9.3.5.2. Financial Performance
9.3.5.3. Service Benchmarking
9.3.5.4. Strategic Initiatives
9.3.6. Catalent, Inc.
9.3.6.1. Company Overview
9.3.6.2. Financial Performance
9.3.6.3. Service Benchmarking
9.3.6.4. Strategic Initiatives
9.3.7. CordenPharma International
9.3.7.1. Company Overview
9.3.7.2. Financial Performance
9.3.7.3. Service Benchmarking
9.3.7.4. Strategic Initiatives
9.3.8. Cambrex Corporation
9.3.8.1. Company Overview
9.3.8.2. Financial Performance
9.3.8.3. Service Benchmarking
9.3.8.4. Strategic Initiatives
9.3.9. Thermo Fisher Scientific, Inc.
9.3.9.1. Company Overview
9.3.9.2. Financial Performance
9.3.9.3. Service Benchmarking
9.3.9.4. Strategic Initiatives
9.3.10. FUJIFILM Diosynth Biotechnologies
9.3.10.1. Company Overview
9.3.10.2. Financial Performance
9.3.10.3. Service Benchmarking
9.3.10.4. Strategic Initiatives
9.3.11. Sumitomo Chemical Company, Limited
9.3.11.1. Company Overview
9.3.11.2. Financial Performance
9.3.11.3. Service Benchmarking
9.3.11.4. Strategic Initiatives
9.3.12. CMIC HOLDINGS Co., LTD.
9.3.12.1. Company Overview
9.3.12.2. Financial Performance
9.3.12.3. Service Benchmarking
9.3.12.4. Strategic Initiatives
9.3.13. Bushu Pharmaceuticals Ltd.
9.3.13.1. Company Overview
9.3.13.2. Financial Performance
9.3.13.3. Service Benchmarking
9.3.13.4. Strategic Initiatives
9.3.14. Nipro Corporation
9.3.14.1. Company Overview
9.3.14.2. Financial Performance
9.3.14.3. Service Benchmarking
9.3.14.4. Strategic Initiatives
LIST OF TABLES
Table 1 List of secondary sources
Table 2 List of Abbreviations
Table 3 Japan Contract Development and Manufacturing Organizations Market, By Product, 2018 - 2030 (USD Million)
Table 4 Japan Contract Development and Manufacturing Organizations Market, By Workflow, 2018 - 2030 (USD Million)
Table 5 Japan Contract Development and Manufacturing Organizations Market, By Application, 2018 - 2030 (USD Million)
Table 6 Japan Contract Development and Manufacturing Organizations Market, Service, 2018 - 2030 (USD Million)
Table 7 Japan Contract Development and Manufacturing Organizations Market, By End Use, 2018 - 2030 (USD Million)
Table 8 ADC Approvals in Japan
Table 9 Financial Performance
Table 10 Key company initiating service launches/upgrades
Table 11 Key companies initiating service launches/upgrades
Table 12 Key companies initiating partnerships
Table 13 Key companies initiating expansion
Table 14 Key companies initiating expansion
Table 1 List of secondary sources
Table 2 List of Abbreviations
Table 3 Japan Contract Development and Manufacturing Organizations Market, By Product, 2018 - 2030 (USD Million)
Table 4 Japan Contract Development and Manufacturing Organizations Market, By Workflow, 2018 - 2030 (USD Million)
Table 5 Japan Contract Development and Manufacturing Organizations Market, By Application, 2018 - 2030 (USD Million)
Table 6 Japan Contract Development and Manufacturing Organizations Market, Service, 2018 - 2030 (USD Million)
Table 7 Japan Contract Development and Manufacturing Organizations Market, By End Use, 2018 - 2030 (USD Million)
Table 8 ADC Approvals in Japan
Table 9 Financial Performance
Table 10 Key company initiating service launches/upgrades
Table 11 Key companies initiating service launches/upgrades
Table 12 Key companies initiating partnerships
Table 13 Key companies initiating expansion
Table 14 Key companies initiating expansion
LIST OF FIGURES
Fig. 1 Information procurement
Fig. 2 Primary research pattern
Fig. 3 Market Research approaches
Fig. 4 Value chain-based sizing & forecasting
Fig. 5 Market formulation & validation
Fig. 6 Japan contract development and manufacturing organizations market segmentation
Fig. 7 Market driver analysis
Fig. 8 Market restraint relevance analysis
Fig. 9 Porter’s five forces analysis
Fig. 10 PESTEL by SWOT analysis
Fig. 11 Regional marketplace: Key takeaways
Fig. 12 Japan synthetic market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 13 Japan solid market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 14 Japan liquid market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 15 Japan biotech market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 16 Japan Traditional Active Pharmaceutical Ingredient (Traditional API) market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 17 Japan Highly Potent Active Pharmaceutical Ingredient (HP-API) market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 18 Japan Antibody Drug Conjugate (ADC) market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 19 Japan others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 20 Japan innovative market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 21 Japan generics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 22 Japan continuous manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 23 Japan batch manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 24 Japan oral solid dose market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 25 Japan semi-solid dose market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 26 Japan liquid dose market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 27 Japan others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 28 Japan innovative market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 29 Japan generics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 30 Japan small molecule market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 31 Japan large molecule market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 32 Japan clinical market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 33 Japan commercial market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 34 Japan oncology market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 35 Japan hormonal market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 36 Japan glaucoma market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 37 Japan cardiovascular disease market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 38 Japan diabetes market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 39 Japan others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 40 Japan contract development market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 41 Japan contract manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 42 Japan packaging market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 43 Japan quality control and assurance market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 44 Japan visual inspection market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 45 Japan others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 46 Japan others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 47 Japan pharmaceutical companies market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 48 Japan biotechnology companies market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 49 Japan others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 1 Information procurement
Fig. 2 Primary research pattern
Fig. 3 Market Research approaches
Fig. 4 Value chain-based sizing & forecasting
Fig. 5 Market formulation & validation
Fig. 6 Japan contract development and manufacturing organizations market segmentation
Fig. 7 Market driver analysis
Fig. 8 Market restraint relevance analysis
Fig. 9 Porter’s five forces analysis
Fig. 10 PESTEL by SWOT analysis
Fig. 11 Regional marketplace: Key takeaways
Fig. 12 Japan synthetic market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 13 Japan solid market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 14 Japan liquid market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 15 Japan biotech market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 16 Japan Traditional Active Pharmaceutical Ingredient (Traditional API) market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 17 Japan Highly Potent Active Pharmaceutical Ingredient (HP-API) market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 18 Japan Antibody Drug Conjugate (ADC) market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 19 Japan others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 20 Japan innovative market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 21 Japan generics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 22 Japan continuous manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 23 Japan batch manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 24 Japan oral solid dose market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 25 Japan semi-solid dose market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 26 Japan liquid dose market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 27 Japan others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 28 Japan innovative market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 29 Japan generics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 30 Japan small molecule market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 31 Japan large molecule market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 32 Japan clinical market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 33 Japan commercial market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 34 Japan oncology market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 35 Japan hormonal market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 36 Japan glaucoma market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 37 Japan cardiovascular disease market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 38 Japan diabetes market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 39 Japan others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 40 Japan contract development market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 41 Japan contract manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 42 Japan packaging market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 43 Japan quality control and assurance market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 44 Japan visual inspection market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 45 Japan others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 46 Japan others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 47 Japan pharmaceutical companies market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 48 Japan biotechnology companies market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 49 Japan others market estimates and forecasts, 2018 - 2030 (USD Million)
